Leukemia Overview: Symptoms, Signs, Treatment and Causes

-



chromosome 17 nf1 :: Article Creator

Learn About Neurofibromatosis

What is NF?

Neurofibromatosis (NF) is a term that refers to at least three distinct, hereditary disorders caused by an abnormality in a gene. These disorders include neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. While NF1 is caused by an alteration, or mutation, in a gene located on chromosome 17, both NF2 and schwannomatosis are caused by mutations in genes located on chromosome 22.

Learn more about the symptoms, diagnosis, causes, and treatment options for each of the three distinct types of neurofibromatosis.

  • Neurofibromatosis type 1 (NF1) is a common inherited neurological disorder affecting about 1 in 3,000 people worldwide. Learn more >
  • Neurofibromatosis type 2 (NF2) affects 1 in 25,000 people and often causes partial or complete hearing loss in both ears. Learn more >
  • Schwannomatosis is a rare form of neurofibromatosis that causes the development of painful tumors on almost any nerve in the body. Learn more >




    • Comments

    Post a Comment

    Popular posts from this blog

    Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

    -
    Image
    Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and...
    Read more

    Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

    -
    Image
    3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t...
    Read more

    Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

    -
    Image
    hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n...
    Read more